187 related articles for article (PubMed ID: 16804565)
1. Vacuolar ATPase as a drug discovery target.
Niikura K
Drug News Perspect; 2006 Apr; 19(3):139-44. PubMed ID: 16804565
[TBL] [Abstract][Full Text] [Related]
2. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
Niikura K; Takeshita N; Takano M
J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
[TBL] [Abstract][Full Text] [Related]
3. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats.
Niikura K; Nakajima S; Takano M; Yamazaki H
Bone; 2007 Apr; 40(4):888-94. PubMed ID: 17157574
[TBL] [Abstract][Full Text] [Related]
4. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
Niikura K; Takano M; Sawada M
Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
[TBL] [Abstract][Full Text] [Related]
5. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
Nyman JK; Väänänen HK
Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
[TBL] [Abstract][Full Text] [Related]
6. Vacuolar H+-ATPase d2 subunit: molecular characterization, developmental regulation, and localization to specialized proton pumps in kidney and bone.
Smith AN; Jouret F; Bord S; Borthwick KJ; Al-Lamki RS; Wagner CA; Ireland DC; Cormier-Daire V; Frattini A; Villa A; Kornak U; Devuyst O; Karet FE
J Am Soc Nephrol; 2005 May; 16(5):1245-56. PubMed ID: 15800125
[TBL] [Abstract][Full Text] [Related]
7. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.
Laitala T; Väänänen HK
J Clin Invest; 1994 Jun; 93(6):2311-8. PubMed ID: 8200964
[TBL] [Abstract][Full Text] [Related]
9. Vacuolar H(+)-ATPase.
Xiao YT; Xiang LX; Shao JZ
Int J Biochem Cell Biol; 2008; 40(10):2002-6. PubMed ID: 17897871
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the osteoclast V-ATPase by small interfering RNAs.
Hu Y; Nyman J; Muhonen P; Väänänen HK; Laitala-Leinonen T
FEBS Lett; 2005 Sep; 579(22):4937-42. PubMed ID: 16115623
[TBL] [Abstract][Full Text] [Related]
11. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.
Xu J; Cheng T; Feng HT; Pavlos NJ; Zheng MH
Histol Histopathol; 2007 Apr; 22(4):443-54. PubMed ID: 17290355
[TBL] [Abstract][Full Text] [Related]
12. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases.
Boyd MR; Farina C; Belfiore P; Gagliardi S; Kim JW; Hayakawa Y; Beutler JA; McKee TC; Bowman BJ; Bowman EJ
J Pharmacol Exp Ther; 2001 Apr; 297(1):114-20. PubMed ID: 11259534
[TBL] [Abstract][Full Text] [Related]
14. Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption - a novel target for treatment of osteoporosis.
Thudium CS; Jensen VK; Karsdal MA; Henriksen K
Curr Protein Pept Sci; 2012 Mar; 13(2):141-51. PubMed ID: 22044152
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor.
Menche D; Hassfeld J; Sasse F; Huss M; Wieczorek H
Bioorg Med Chem Lett; 2007 Mar; 17(6):1732-5. PubMed ID: 17239591
[TBL] [Abstract][Full Text] [Related]
16. Energizing an invertebrate embryo: bafilomycin-dependent respiration and the metabolic cost of proton pumping by the V-ATPase.
Covi JA; Hand SC
Physiol Biochem Zool; 2007; 80(4):422-32. PubMed ID: 17508337
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the vacuolar H(+)-pump with bafilomycin A1 does not induce acrosome reaction or activate proacrosin in mouse spermatozoa.
Codelia VA; Cortes CJ; Moreno RD
Biochem Biophys Res Commun; 2005 Dec; 337(4):1337-44. PubMed ID: 16236270
[TBL] [Abstract][Full Text] [Related]
18. Effects of Bafilomycin A1: an inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts.
Xu J; Feng HT; Wang C; Yip KH; Pavlos N; Papadimitriou JM; Wood D; Zheng MH
J Cell Biochem; 2003 Apr; 88(6):1256-64. PubMed ID: 12647307
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of osteoclast vacuolar H(+)-ATPase.
Farina C; Gagliardi S
Curr Pharm Des; 2002; 8(23):2033-48. PubMed ID: 12171517
[TBL] [Abstract][Full Text] [Related]
20. Plasmalemmal vacuolar-type H+-ATPase in cancer biology.
Sennoune SR; Luo D; Martínez-Zaguilán R
Cell Biochem Biophys; 2004; 40(2):185-206. PubMed ID: 15054222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
